Skip to main content
QNCX logo

Quince Therapeutics, Inc.

QNCXNASDAQHealthcareBiotechnology

$33.23Today:- (-)1Y +1621.76%

As of Oct 15, 2026 close

Market cap
$203.79M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.80$76.86
Volume (live)
-
Avg. volume (3M)
30.16K

Quince Therapeutics (QNCX) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Quince Therapeutics used $41.42M of cash in operating activities and spent $352.00K on capital expenditures. That left free cash flow of −$41.78M.

Quince Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Quince Therapeutics, Inc. (QNCX) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Mar 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-83.98-56.83-31.39-31.39-51.66-89.95-76.85-36.98-12.48-12.24
Depreciation & Amortization0.140.190.320.320.200.340.330.190.050.05
Deferred Income Tax-4.960.00-0.25--0.280.880.64-0.81-0.150.22
Stock Based Compensation5.114.755.225.2216.6229.8514.472.060.160.04
Change in Working Capital12.84-0.481.981.98-9.83-4.2610.231.90-0.390.46
Change in Accounts Payable-0.940.93-0.29-0.29-5.941.360.482.58-0.020.22
Change in Other Working Capital13.78-2.482.271.67-3.89-0.989.75-0.68-0.370.24
Other Operating Activities29.4320.485.821.670.911.080.370.371.111.64
Net Cash from Operating Activities-41.43-31.90-18.29-18.29-44.04-62.93-50.82-33.28-11.70-9.83
Investing Activities
Capital Expenditures-0.35-0.26-0.16-0.16-0.13-0.18-0.05-0.06-0.21-0.08
Acquisitions0.000.00-2.12-2.1210.59-58.9552.43-0.810.000.00
Purchases of Investments-34.42-89.56-113.78-113.78-75.02-38.79-52.38-135.42-55.240.00
Sales/Maturities of Investments56.98111.73111.21111.2182.4997.92134.76117.728.700.00
Other Investing Activities1.012.35-0.91-1.000.0758.95-52.430.81-46.540.00
Net Cash from Investing Activities23.2321.91-5.76-5.7618.0058.95-52.43-17.75-46.75-0.08
Financing Activities
Debt Repayment0.000.00-0.01-0.01-0.050.00-0.03-0.560.257.75
Common Stock Issued17.910.230.150.150.616.81118.9177.8375.680.00
Other Financing Activities0.00-5.000.00-0.010.150.00-0.030.1075.680.00
Net Cash from Financing Activities17.91-4.780.140.140.716.81118.8877.3775.937.75
Summary
Effect of Forex Changes on Cash-0.110.230.080.080.180.060.000.000.000.00
Net Change in Cash-0.40-14.54-23.83-23.83-25.152.8815.6326.3417.48-2.15
Cash at Beginning of Period6.2120.7544.5844.5869.7266.8451.2124.877.399.55
Cash at End of Period5.816.2120.7520.7544.5869.7266.8451.2124.877.39
Free Cash Flow-41.78-32.16-18.45-18.45-44.17-63.11-50.87-33.33-11.91-9.90

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Quince Therapeutics Cash Flow

What is Quince Therapeutics's free cash flow?

Quince Therapeutics had negative free cash flow of $41.78M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$41.42M minus $352.00K of capital expenditures.

How much does Quince Therapeutics spend on capital expenditures?

Quince Therapeutics spent $352.00K on capital expenditures in fiscal 2025, compared with $257.00K a year earlier.

Does Quince Therapeutics pay dividends or buy back shares?

Quince Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition